Risk of Recurrence after Surgical Resection for Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasia (IPMN) with Patterns of Distribution and Treatment

医学 比例危险模型 腺癌 队列 内科学 对数秩检验 胃肠病学 外科 生存分析 阶段(地层学) 癌症 古生物学 生物
作者
James Lucocq,Jake Hawkyard,Francis P. Robertson,Beate Haugk,Jonathan Lye,Daniel Parkinson,Steve White,Omar Mownah,Yoh Zen,Krishna Menon,Takaaki Furukawa,Yosuke Inoue,Yuki Hirose,Naoki Sasahira,Michael Feretis,Anita Balakrishnan,Piotr Zelga,Carlo Ceresa,Brian R Davidson,Rupaly Pandé
出处
期刊:Annals of Surgery [Ovid Technologies (Wolters Kluwer)]
被引量:9
标识
DOI:10.1097/sla.0000000000006144
摘要

Objective: This international multicentre cohort study aims to identify recurrence patterns and treatment of first and second recurrence in a large cohort of patients after pancreatic resection for adenocarcinoma arising from IPMN. Summary Background Data: Recurrence patterns and treatment of recurrence post resection of adenocarcinoma arising from IPMN are poorly explored. Method: Patients undergoing pancreatic resection for adenocarcinoma from IPMN between January 2010 to December 2020 at 18 pancreatic centres were identified. Survival analysis was performed by the Kaplan-Meier log rank test and multivariable logistic regression by Cox-Proportional Hazards modelling. Endpoints were recurrence (time-to, location, and pattern of recurrence) and survival (overall survival and adjusted for treatment provided). Results: Four hundred and fifty-nine patients were included (median, 70 y; IQR, 64-76; male, 54 percent) with a median follow-up of 26.3 months (IQR, 13.0-48.1 mo). Recurrence occurred in 209 patients (45.5 percent; median time to recurrence, 32.8 months, early recurrence [within 1 y], 23.2 percent). Eighty-three (18.1 percent) patients experienced a local regional recurrence and 164 (35.7 percent) patients experienced distant recurrence. Adjuvant chemotherapy was not associated with reduction in recurrence (HR 1.09; P =0.669) One hundred and twenty patients with recurrence received further treatment. The median survival with and without additional treatment was 27.0 and 14.6 months ( P <0.001), with no significant difference between treatment modalities. There was no significant difference in survival between location of recurrence ( P =0.401). Conclusion: Recurrence after pancreatic resection for adenocarcinoma arising from IPMN is frequent with a quarter of patients recurring within 12 months. Treatment of recurrence is associated with improved overall survival and should be considered.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
math-naive完成签到,获得积分10
1秒前
111完成签到 ,获得积分10
2秒前
考槃在涧完成签到 ,获得积分10
2秒前
跳跃的访琴完成签到 ,获得积分10
2秒前
科研牛马完成签到 ,获得积分10
2秒前
MM完成签到,获得积分10
5秒前
Arrhenius完成签到,获得积分10
5秒前
6秒前
神志不清的衾完成签到,获得积分10
8秒前
活泼的大船完成签到,获得积分10
8秒前
Pan完成签到 ,获得积分10
8秒前
摇摇摇不匀完成签到 ,获得积分10
8秒前
Zhaowx完成签到,获得积分10
10秒前
藏识完成签到,获得积分10
10秒前
要奋斗的小番茄完成签到,获得积分10
11秒前
12秒前
自由人完成签到,获得积分10
13秒前
13秒前
15秒前
15秒前
感动天荷完成签到,获得积分10
17秒前
Autaro完成签到,获得积分10
17秒前
18秒前
量子星尘发布了新的文献求助150
18秒前
尛森发布了新的文献求助10
19秒前
19秒前
abjz完成签到,获得积分10
19秒前
20秒前
Inversaydie完成签到,获得积分10
20秒前
子车茗应助科研通管家采纳,获得20
21秒前
CodeCraft应助科研通管家采纳,获得10
21秒前
彭于晏应助科研通管家采纳,获得10
21秒前
刘东妮应助科研通管家采纳,获得10
21秒前
无花果应助科研通管家采纳,获得10
21秒前
酷波er应助科研通管家采纳,获得10
21秒前
一兜哇应助科研通管家采纳,获得20
21秒前
TYMY应助科研通管家采纳,获得20
21秒前
机智的皮皮虾完成签到,获得积分10
21秒前
Lucas应助科研通管家采纳,获得10
21秒前
子车茗应助科研通管家采纳,获得20
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
The Social Work Ethics Casebook: Cases and Commentary (revised 2nd ed.).. Frederic G. Reamer 1070
Introduction to Early Childhood Education 1000
2025-2031年中国兽用抗生素行业发展深度调研与未来趋势报告 1000
List of 1,091 Public Pension Profiles by Region 871
The International Law of the Sea (fourth edition) 800
A Guide to Genetic Counseling, 3rd Edition 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 纳米技术 计算机科学 内科学 化学工程 复合材料 物理化学 基因 遗传学 催化作用 冶金 量子力学 光电子学
热门帖子
关注 科研通微信公众号,转发送积分 5418754
求助须知:如何正确求助?哪些是违规求助? 4534384
关于积分的说明 14143702
捐赠科研通 4450621
什么是DOI,文献DOI怎么找? 2441331
邀请新用户注册赠送积分活动 1433030
关于科研通互助平台的介绍 1410467